OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine

October 17th, 2017|0 Comments

BATON ROUGE, La., Oct. 17, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia

September 29th, 2017|0 Comments

BATON ROUGE, La., Sept. 29, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer

September 14th, 2017|0 Comments

BATON ROUGE, LA, Sept. 14, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment

August 31st, 2017|0 Comments

BATON ROUGE, LA--(August 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a [...]

OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference

August 29th, 2017|0 Comments

BATON ROUGE, LA--(August 29, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer

August 24th, 2017|0 Comments

BATON ROUGE, LA--(August 24, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico

August 22nd, 2017|0 Comments

BATON ROUGE, LA--(August 22, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico

August 10th, 2017|0 Comments

BATON ROUGE, LA--(August 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico

August 3rd, 2017|0 Comments

BATON ROUGE, LA--(August 3, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Acquires Propolis Product Line from German Partner

July 20th, 2017|0 Comments

BATON ROUGE, LA--(July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement

July 13th, 2017|0 Comments

BATON ROUGE, LA--(July 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico

June 28th, 2017|0 Comments

BATON ROUGE, LA--(June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

Enrollment to Begin in OncBioMune’s Trial of ProscaVax for Prostate Cancer in Mexico

June 27th, 2017|0 Comments

BATON ROUGE, LA—(June 27, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

June 21st, 2017|0 Comments

BATON ROUGE, LA—(June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Awarded Patent for ProscaVax in Japan

June 20th, 2017|0 Comments

BATON ROUGE, LA--(June 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

June 19th, 2017|0 Comments

MEXICO CITY, MEXICO--(June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted [...]

OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)

June 15th, 2017|0 Comments

BATON ROUGE, LA--(June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong

June 7th, 2017|0 Comments

BATON ROUGE, LA--(June 07, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]

OncBioMune’s Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility

June 6th, 2017|0 Comments

BATON ROUGE, LA--(June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]

Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer

June 1st, 2017|0 Comments

BATON ROUGE, LA—(June 01, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]